Stephen Smolinski - Jan 4, 2022 Form 4 Insider Report for Avalo Therapeutics, Inc. (AVTX)

Role
Chief Commercial Officer
Signature
/s/ Christopher Sullivan, Attorney-in-Fact
Stock symbol
AVTX
Transactions as of
Jan 4, 2022
Transactions value $
$0
Form type
4
Date filed
1/6/2022, 03:19 PM
Previous filing
Jan 6, 2022

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction AVTX Stock Option (Right to Buy) Award $0 +400K $0.00 400K Jan 4, 2022 Common Stock 400K $1.70 Direct F1
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 The stock option will vest over four years, with the first 25% vesting on the first anniversary of the grant date, and the remainder vesting in equal monthly installments over the following 36 months, subject to the reporting person's continued service on each such vesting date.